ClinicalTrials.gg
CompletedNCT01731002Updated Apr 17, 2018Results posted

Study Comparing the Safety and Efficacy of AR-13324 to Latanoprost in Patients With Elevated Intraocular Pressure

A Phase 2 interventional study of AR-13324 Ophthalmic Solution 0.01% and AR-13324 Ophthalmic Solution 0.02% in Ocular Hypertension and Open Angle Glaucoma, sponsored by Aerie Pharmaceuticals. Completed at 22 sites in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2018-04-17.

Primary conditionGlaucoma, Open-AngleRegistry: Ocular HypertensionReclassifiedWhy we changed it
Registry
Ocular Hypertension — the first condition term the registry derived for this study.
ClinicalTrials.gg
Glaucoma, Open-Angle
Why
  1. The study's listed conditions name Glaucoma, Open-Angle, a narrower term within Ocular Hypertension.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Aerie Pharmaceuticals (part of Alcon) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
224
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing netarsudil in Glaucoma, Open-Angle — 3 open to participants now, 4 under way, none of them phase 3. netarsudil · Glaucoma, Open-Angle.

Enrollment
7th of 17
224 · median 85
Started
2012
with 1 other
Phase 2
6 of 17
none open now
Registered
2nd of 17
by date
Lead sponsor
11 of 17
Aerie Pharmaceuticals

Among the 17 studies testing netarsudil in Glaucoma, Open-Angle, this one is the 7th largest by enrollment, is one of 2 that started in 2012, is one of 6 in phase 2, and was the 2nd registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

3 of the 17 studies testing netarsudil in Glaucoma, Open-Angle are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

About netarsudil

netarsudil: first FDA approval 2017 (RHOPRESSA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing netarsudil in Glaucoma, Open-Angle, or all of them as a file.
02

Study summary

Double-masked, randomized, multi-center, dose-response, active-controlled parallel-comparison of AR-13324 to latanoprost

03

Conditions studied

  • Ocular Hypertension
  • Open Angle Glaucoma

Browse trials for

Keywords

  • Glaucoma
04

In context

Glaucoma, Open-Angle Reclassified

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

This study's enrollment of 224 is above the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.

Browse Glaucoma, Open-Angle studies →

Lead sponsor

Aerie Pharmaceuticals is the lead sponsor of 36 studies on the registry; none are open to participants now.

Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.

First submitted before Aerie Pharmaceuticals became part of Alcon.

Compared within Glaucoma, Open-Angle, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Ocular Hypertension. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 years of age or greater.
  2. Diagnosis of open angle glaucoma (OAG) or ocular hypertension (OHT).
  3. Unmedicated (post-washout) Intraocular Pressure (IOP) ≥ 24 mm Hg at 2 eligibility visits (08:00 hr), 2-7 days a part, and ≥ 22 mm Hg at 10:00 and 16:00 hrs at the second qualification visit. If only one eye meets the IOP criteria it must be the same eye that met the criteria at all the qualification timepoints.
  4. Corrected visual acuity in each eye +1.0 logMAR or better by ETDRS in each eye (equivalent to 20/200).
  5. Able and willing to give signed and follow study instructions.

Exclusion criteria

Exclusion Criteria:

Ophthalmic

  1. Glaucoma: pseudoexfoliation or pigment dispersion component, history of angle closure or narrow angles. Note: Previous laser peripheral iridotomy is NOT acceptable.
  2. IOP > 36 mm Hg.
  3. Known to any component of the formulation (benzalkonium chloride, etc.), or to topical anesthetics.
  4. Previous glaucoma intraocular surgery or glaucoma laser procedures in study eye(s, e.g., laser trabeculoplasty).
  5. Refractive surgery in study eye(s) (e.g., radial keratotomy, photorefractive keratectomy (PRK), laser eye surgery (LASIK), etc.).
  6. Ocular trauma within the past six months, or ocular surgery or laser treatment within the past three months prior to screening.
  7. Evidence of ocular infection, inflammation, blepharitis or conjunctivitis at screening (Visit 0), or a history of herpes simplex keratitis
  8. Ocular medication of any kind within 30 days of Visit 0, with the exception of a) ocular hypotensive medications (which must be washed out according to the provided schedule), b) lid scrubs (which may be used prior to, but not after Visit 0) or c) lubricating drops for dry eye (which may be used throughout the study).
  9. Clinically significant ocular disease (e.g. uveitis, severe keratoconjunctivitis sicca) which might interfere with the study, including glaucomatous damage so severe that washout of ocular hypotensive medications for one month is not judged safe (i.e., cup-disc ratio > 0.8).
  10. Central corneal thickness greater than 600 µm.
  11. Any abnormality preventing reliable applanation tonometry of either eye.

    Systemic:

  12. Clinically significant abnormalities (as determined by the treating physician) in laboratory tests at screening.
  13. Known hypersensitivity or to latanoprost.
  14. Clinically significant systemic disease (e.g., myasthenia gravis, hepatic, renal, endocrine or cardiovascular disorders) which might interfere with the study.
  15. Participation in any study within 30 days prior to screening.
  16. Changes of systemic medication that could have a substantial effect on IOP within 30 days prior to screening, or anticipated during the study.
  17. Due to the current status of the preclinical safety program, women of who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of . An adult woman is considered to be of childbearing potential unless she is one year or three months post-surgical sterilization. All females of childbearing potential must have a negative urine pregnancy test result at the screening examination and must not intend to become pregnant during the study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
224 participants (actual)

Study arms

  • Experimental
    AR-13324 Ophthalmic Solution 0.01%

    1 drop to study eye once daily

    Drug: AR-13324 Ophthalmic Solution 0.01%

  • Experimental
    AR-13324 Ophthalmic Solution 0.02%

    1 drop to study eye once daily

    Drug: AR-13324 Ophthalmic Solution 0.02%

  • Active comparator
    Latanoprost Ophthalmic Solution 0.005%

    1 drop to study eye once daily

    Drug: Latanoprost ophthalmic solution 0.005%

Interventions

07

What researchers measure

Primary outcomes

  1. Intraocular Pressure (IOP)

    The primary efficacy endpoint was the mean IOP across subjects within treatment group on each day at each post-treatment timepoint. IOP was measured at 0800, 1000, and 1600 hours on days 0, 14, and 28. IOP was also measured at 0800 hours on Day 7 and follow-up days 29 and 30.

    Time frame: Study treatment was administered for 28 days

Secondary outcomes

  1. Extent of Exposure

    Exposure to study medication in days for all treatment groups.

    Time frame: 28 Days

08

Results

Posted Apr 17, 2018

Participant flow

Participant flow — Overall Study
MilestoneAR-13324 Ophthalmic Solution 0.01%AR-13324 Ophthalmic Solution 0.02%Latanoprost Ophthalmic Solution 0.005%
Started757277
Completed716874
Not completed443
Withdrew: Adverse event022
Withdrew: Non-compliant010
Withdrew: Lost to follow-up100
Withdrew: Test agent discontinuation010
Withdrew: Uncontrolled intraocular pressure (iop)200
Withdrew: Elevated iop100
Withdrew: Inappropriate use of study medications001

Outcome measures

PrimaryIntraocular Pressure (IOP)

The primary efficacy endpoint was the mean IOP across subjects within treatment group on each day at each post-treatment timepoint. IOP was measured at 0800, 1000, and 1600 hours on days 0, 14, and 28. IOP was also measured at 0800 hours on Day 7 and follow-up days 29 and 30.

Time frame:
Study treatment was administered for 28 days
Reported as:
Mean · mmHg
Intraocular Pressure (IOP)
mmHgAR-13324 Ophthalmic Solution 0.01%AR-13324 Ophthalmic Solution 0.02%Latanoprost Ophthalmic Solution 0.005%
Day 0, 0800 hours27.34 ± 3.52927.11 ± 3.03126.78 ± 2.749
Day 0, 1000 hours25.55 ± 3.41125.41 ± 3.02425.18 ± 2.719
Day 0, 1600 hours24.49 ± 3.12824.29 ± 2.60224.58 ± 2.515
Day 7, 0800 hours21.89 ± 4.67221.15 ± 4.04720.03 ± 3.173
Day 14, 0800 hours21.24 ± 4.29520.80 ± 3.67919.30 ± 3.033
Day 14, 1000 hours19.28 ± 3.58118.88 ± 3.46118.09 ± 2.884
Day 14, 1600 hours18.90 ± 3.57818.72 ± 3.58517.86 ± 2.977
Day 28, 0800 hours21.95 ± 4.71721.24 ± 4.03419.24 ± 2.899
Day 28, 1000 hours19.69 ± 4.35819.53 ± 3.72618.40 ± 2.994
Day 28, 1600 hours18.82 ± 3.28119.13 ± 3.65618.34 ± 3.052
SecondaryExtent of Exposure

Exposure to study medication in days for all treatment groups.

Time frame:
28 Days
Reported as:
Mean · days
Extent of Exposure
daysAR-13324 Ophthalmic Solution 0.01%AR-13324 Ophthalmic Solution 0.02%Latanoprost Ophthalmic Solution 0.005%
Extent of Exposure27.6 ± 4.0726.8 ± 4.627.8 ± 1.35

Adverse events

Collected over 28 Days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AR-13324 Ophthalmic Solution 0.01%1/75 (1.3%)1/75 (1.3%)43/75 (57.3%)
AR-13324 Ophthalmic Solution 0.02%0/72 (0%)0/72 (0%)45/72 (62.5%)
Latanoprost Ophthalmic Solution 0.005%0/77 (0%)2/77 (2.6%)18/77 (23.4%)
Most frequent serious events
Most frequent serious events
EventAR-13324 Ophthalmic Solution 0.01%AR-13324 Ophthalmic Solution 0.02%Latanoprost Ophthalmic Solution 0.005%
Acute LeukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/750/720/77
Pneumonia StreptococcalInfections and infestations0/750/721/77
FallInjury, poisoning and procedural complications0/750/721/77
Most frequent other events
Most frequent other events
EventAR-13324 Ophthalmic Solution 0.01%AR-13324 Ophthalmic Solution 0.02%Latanoprost Ophthalmic Solution 0.005%
Conjunctival HyperaemiaEye disorders29/7534/7212/77
Ocular HyperaemiaEye disorders10/757/720/77
Instillation Site PainGeneral disorders5/759/724/77
Lacrimation IncreasedEye disorders4/755/720/77
Foreign Body Sensation in EyesEye disorders0/755/723/77
Conjunctival HaemorrhageEye disorders4/754/720/77

Baseline characteristics

Age, Continuous
Age, Continuous(years)AR-13324 Ophthalmic Solution 0.01%AR-13324 Ophthalmic Solution 0.02%Latanoprost Ophthalmic Solution 0.005%Total
Mean63.5 ± 11.5466.3 ± 10.2565.7 ± 11.8265.1 ± 11.26
Sex: Female, Male
Sex: Female, Male(Participants)AR-13324 Ophthalmic Solution 0.01%AR-13324 Ophthalmic Solution 0.02%Latanoprost Ophthalmic Solution 0.005%Total
Female424545132
Male33273292
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)AR-13324 Ophthalmic Solution 0.01%AR-13324 Ophthalmic Solution 0.02%Latanoprost Ophthalmic Solution 0.005%Total
Hispanic or Latino16151546
Not Hispanic or Latino595762178
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)AR-13324 Ophthalmic Solution 0.01%AR-13324 Ophthalmic Solution 0.02%Latanoprost Ophthalmic Solution 0.005%Total
American Indian or Alaska Native0000
Asian2204
Native Hawaiian or Other Pacific Islander0000
Black or African American17161952
White565358167
More than one race0000
Unknown or Not Reported0101
09

Study locations

22 sites
  • Kenneth Sall, M.D.
    Artesia, California 90701, United States
  • United Medical Research Institute
    Inglewood, California 90301, United States
  • Aesthetic Eye Care Institute
    Newport Beach, California 92657, United States
  • North Bay Eye Associates
    Petaluma, California 94954, United States
  • Centre For Health Care
    Poway, California 92064, United States
  • Clayton Eye Center
    Morrow, Georgia 30260, United States
  • Coastal Research Associates, LLC
    Roswell, Georgia 30076, United States
  • Bradley Kwapiszeski, MD
    Shawnee Mission, Kansas 66204, United States
  • Taustine Eye Center
    Louisville, Kentucky 40217, United States
  • Alan L Robin, M.D.
    Baltimore, Maryland 21209, United States
  • Seidenberg Protzko Eye Associates
    Havre De Grace, Maryland 21078, United States
  • Great Lakes Eye Care
    Saint Joseph, Michigan 49085, United States
  • Ophthalmic Consultants of Long Island
    Lynbrook, New York 11563, United States
  • Rochester Ophthalmological Group
    Rochester, New York 14618, United States
  • Charlotte Eye Ear Nose and Throat
    Charlotte, North Carolina 28210, United States
  • Michael E. Tepedino, M.D.
    High Point, North Carolina 27262, United States
  • The Eye Institute
    Tulsa, Oklahoma 74104, United States
  • Wills Eye Hospital
    Philadelphia, Pennsylvania 19107, United States
  • Texan Eye
    Austin, Texas 78731, United States
  • Cataract & Glaucoma Center
    El Paso, Texas 79902, United States
  • Medical Center Ophth. Associates
    San Antonio, Texas 78731, United States
  • Virginia Eye Consultants
    Norfolk, Virginia 23502, United States
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2012, a primary completion of May 2013 and a completion of May 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2018, 4 years 11 months after primary completion. A results delay was requested in Feb 2014.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2012
First posted
Nov 21, 2012
Start
Nov 2012
Primary completionActual
May 2013
CompletionActual
May 2013
Results delay requested
Feb 17, 2014
Results first posted
Apr 17, 2018
Last update
Apr 17, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01731002
Responsible party
Sponsor
First posted
Nov 21, 2012
Start date
Nov 2012
Primary completion
May 2013
Completion
May 2013
Results posted
Apr 17, 2018
Last update
Apr 17, 2018

Study contacts

Theresa Heah, MD
study director · Aerie Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Netarsudil

Start the discussion